Potassium-competitive acid blockers and gastroesophageal reflux disease
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved..
Proton pump inhibitors (PPIs), the most commonly used antisecretory medi-cations in the management of reflux illness, virtually eliminate elective surgery for ulcer disease, and relegate anti-reflux surgery to patients with gastroesophageal reflux disease (GERD) who are inadequately managed by medical therapy. However, PPI medications still leave some therapeutic demands of GERD unmet. Furthermore, up to 40%-55% of daily PPI users have chronic symptoms, due to PPI refractoriness. Potassium-competitive acid blockers (P-CABs) transcend many of the problems and limits of PPIs, delivering quick, powerful, and extended acid suppression and allowing for treatment of numerous unmet needs. Recently, it has become clear that compromised mucosal integrity plays a role in the etiology of GERD. As a result, esophageal mucosal protection has emerged as a novel and potential treatment approach. An increasing body of research demonstrates that when P-CABs are used as primary drugs or add-on drugs (to regular treatment), they provide a considerable extra benefit, particularly in alleviating symptoms that do not respond to PPI therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
World journal of gastroenterology - 28(2022), 28 vom: 28. Juli, Seite 3608-3619 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leowattana, Wattana [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 28.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3748/wjg.v28.i28.3608 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346772966 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346772966 | ||
| 003 | DE-627 | ||
| 005 | 20231226032240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3748/wjg.v28.i28.3608 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346772966 | ||
| 035 | |a (NLM)36161043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leowattana, Wattana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potassium-competitive acid blockers and gastroesophageal reflux disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a Proton pump inhibitors (PPIs), the most commonly used antisecretory medi-cations in the management of reflux illness, virtually eliminate elective surgery for ulcer disease, and relegate anti-reflux surgery to patients with gastroesophageal reflux disease (GERD) who are inadequately managed by medical therapy. However, PPI medications still leave some therapeutic demands of GERD unmet. Furthermore, up to 40%-55% of daily PPI users have chronic symptoms, due to PPI refractoriness. Potassium-competitive acid blockers (P-CABs) transcend many of the problems and limits of PPIs, delivering quick, powerful, and extended acid suppression and allowing for treatment of numerous unmet needs. Recently, it has become clear that compromised mucosal integrity plays a role in the etiology of GERD. As a result, esophageal mucosal protection has emerged as a novel and potential treatment approach. An increasing body of research demonstrates that when P-CABs are used as primary drugs or add-on drugs (to regular treatment), they provide a considerable extra benefit, particularly in alleviating symptoms that do not respond to PPI therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Esophageal mucosal resistance | |
| 650 | 4 | |a Gastroesophageal reflux disease | |
| 650 | 4 | |a Potassium-competitive acid blocker | |
| 650 | 4 | |a Proton pump inhibitor-refractory patients | |
| 650 | 4 | |a Proton pump inhibitors | |
| 650 | 4 | |a Treatment outcome | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 700 | 1 | |a Leowattana, Tawithep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of gastroenterology |d 1997 |g 28(2022), 28 vom: 28. Juli, Seite 3608-3619 |w (DE-627)NLM117065250 |x 2219-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:28 |g day:28 |g month:07 |g pages:3608-3619 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3748/wjg.v28.i28.3608 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 28 |b 28 |c 07 |h 3608-3619 | ||